MedWatch

Barclays analysis leaves Demant and GN Hearing out in the cold

Although the British bank sees the potential for clear skies on the horizon, there are too many unknowns for Barclays to recommend investing in the two Danish hearing aid manufacturers.

A GN Hearing product | Photo: PR / GN

Even if hearing aid manufacturers that have been hit by a negative investing mood face an upswing soon, it won’t be enough to offset the headwinds for two companies in particular, GN Hearing and Demant, assesses British bank Barclays according to Bloomberg.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs